PPARG
PPARG
Overview
Peroxisome proliferator-activated receptor gamma (PPARγ), encoded by the PPARG gene (Wikidata: Q20970208), is a ligand-activated nuclear receptor and transcription factor belonging to the nuclear receptor superfamily. It is most highly expressed in adipose tissue but is also present in macrophages, the colon, skeletal muscle, and the central nervous system. PPARγ functions as a master regulator of adipogenesis and lipid metabolism, orchestrating the transcriptional programs that govern fat cell differentiation, fatty acid storage, and glucose homeostasis. Upon activation by endogenous ligands — including polyunsaturated fatty acids and eicosanoids — or pharmacological agonists such as thiazolidinediones, PPARγ forms obligate heterodimers with retinoid X receptors (RXRs) and binds to peroxisome proliferator response elements (PPREs) in target gene promoters to regulate downstream transcription.
Beyond its canonical metabolic roles, PPARγ exerts broad anti-inflammatory effects by antagonizing nuclear factor kappa B (NF-κB) signaling and suppressing pro-inflammatory cytokine production, including interleukin-6. These dual metabolic and immunomodulatory functions have made PPARγ a high-value therapeutic target across a spectrum of conditions ranging from type 2 diabetes and non-alcoholic fatty liver disease to neurological injury and chronic inflammation. Its close paralog, PPARα (encoded by PPARA), governs fatty acid oxidation in complementary fashion, and the interplay between PPARγ and PPARα is a recurring theme in studies of lipid homeostasis and metabolic disease.
Recent Publications Focus
Below is a summary of the newest research publications targeting PPARG (sorted by publication date).
Recent studies have established PPARG as a high-priority therapeutic target spanning inflammatory, metabolic, and neurological disease contexts. PPARG's multifaceted roles in regulating mitochondrial homeostasis, immunometabolic function, and inflammatory resolution have prompted investigation into both PPARG activation and modulation strategies. Network pharmacology analysis has identified PPARG as a central hub gene within disease-associated immune-inflammatory pathways, including those linking gut microbiota-derived metabolites to Alzheimer's disease pathology [42406869].
PPARG activation has demonstrated efficacy in treating oxidative stress-driven inflammatory conditions. In radiation-induced lung injury, a novel inhalable, reactive oxygen species-responsive nanospray formulation containing nicotinamide adenine dinucleotide (NAD+) and astaxanthin was designed to cooperatively activate PPAR-γ: NAD+ promotes SIRT1-mediated deacetylation of PPAR-γ while astaxanthin serves as an activating ligand [42417470]. This dual-activation strategy restored macrophage mitochondrial homeostasis by coordinating mitochondrial biogenesis and mitophagy, promoting a reparative macrophage phenotype and markedly attenuating lung injury with improved survival in murine models of thoracic and whole-body irradiation. Following subarachnoid hemorrhage, exosome-mediated delivery of miR-27a-3p antagomirs indirectly activated PPAR-γ by blocking miR-27a-3p-mediated inhibition, thereby alleviating white matter injury through suppression of oligodendrocyte apoptosis and promotion of oligodendrocyte precursor cell proliferation [41581691]. This mechanism involved PPAR-γ-dependent downregulation of PRDX1 and suppression of JNK pathway activation.
PPARG represents a multi-target hub for metabolic disease intervention, with therapeutic approaches showing distinct regulatory strategies depending on disease context. In type 2 diabetes, natural compounds including xanthohumol and cirsilineol were identified through computational screening to target PPARG alongside five additional metabolic regulators [41923660]; all five lead compounds significantly enhanced insulin-stimulated glucose uptake in adipocytes, with xanthohumol and cirsilineol additionally increasing glucose-stimulated insulin secretion in pancreatic β-cells to levels comparable to exendin-4. In alcoholic fatty liver disease, fermented pine pollen suppressed PPAR-γ expression to inhibit lipogenesis via SREBP-1c downregulation, while simultaneously promoting fatty acid oxidation through PPAR-α and CPT1 upregulation [41762882], resulting in marked reductions in hepatic triglyceride levels and serum alanine aminotransferase. These context-dependent regulatory strategies highlight the nuanced pharmacology of PPARG across metabolic diseases. Additionally, PPARG has been identified as a hub gene in network models exploring immune-inflammatory pathways by which gut microbiota-derived metabolites may regulate Alzheimer's disease [42406869], and short-term intravenous lipid emulsion exposure was found to not significantly affect PPARG expression in fetal skeletal muscle [41955312], suggesting tissue and developmental context-specificity in PPARG responsiveness to metabolic stimuli.